Humacyte Q3 Revenue Doubles as Symvess Hits $1M

# Humacyte Q3 Revenue Doubles as Symvess Hits $1M

Humacyte, Inc. (Nasdaq: HUMA) reported third-quarter 2026 commercial sales of Symvess of $1.0 million, a 151% increase over the second quarter's $0.4 million, the company announced on 10 November 2026. The bioengineered-tissue developer also said October 2026 sales reached $0.8 million and that it expects fourth-quarter revenue to at least double the third-quarter figure. Net loss narrowed to $15.5 million from $17.5 million a year earlier, while cash, cash equivalents and restricted cash stood at $64.9 million as of 30 September 2026.

Context — why this quarter matters for Humacyte

Humacyte's revenue base is small, so the sequential jump is the clearest signal yet that its commercial reset is producing orders. The company said the number of hospitals ordering Symvess rose 44%, from 34 at the end of the second quarter to 49 as of 30 September 2026, and that new hospital orders increased sequentially each month of the quarter.

The prior-year comparison is less flattering in isolation: third-quarter 2025 Symvess sales were $0.7 million, so the year-over-year gain is roughly 43%, well below the 151% sequential rate. The company attributes the acceleration to commercialization initiatives implemented during the first half of 2026, not to a change in the underlying product label.

What changed now is the breadth of the buyer base. A single hospital reordering can swing a $1.0 million quarter, so the 15-hospital increase is the more durable datapoint than the revenue line itself. Humacyte said it anticipates adding at least 20 new hospitals during the second half of 2026.

On the pipeline side, Humacyte said it plans to file a supplemental Biologics License Application with the FDA in November 2026 to add dialysis access as a second approved indication for its acellular tissue engineered vessel, or ATEV. That filing rests on three Phase 3 studies, two of which have now been disclosed publicly.

The broader market backdrop is not in the report, and Humacyte's share price reaction was not disclosed in the release. The company did not provide full-year 2026 revenue guidance or a cash runway estimate.

Data — what the numbers show

The quarter's figures trace a company still spending far more than it sells. Research and development expenses were $14.1 million for the quarter, down from $17.3 million a year earlier and $4.0 million below the second quarter's $18.1 million. General and administrative expenses rose to $9.0 million from $7.6 million, which the company tied to a $0.6 million net reserve for shareholder litigation settlement plus related legal costs.

Cost of goods sold was $1.4 million, against $0.3 million a year earlier. Of that, $0.6 million covered units actually sold, while $0.8 million was overhead tied to unused production capacity and royalties — meaning the reported gross margin on Symvess is negative on a fully loaded basis.

Metric	Q3 2026	Q2 2026	Q3 2025
Symvess sales	$1.0M	$0.4M	$0.7M
R&D expense	$14.1M	$18.1M	$17.3M
Net loss	$15.5M	—	$17.5M
Hospitals ordering	49	34	—

Nine-month Symvess sales were $1.9 million versus $1.0 million in the same 2025 period. Net cash used in operations fell to $15.0 million for the quarter from $23.9 million a year earlier, and to $62.1 million for the nine months from $78.9 million.

Other net income of $8.0 million for the quarter came primarily from non-cash remeasurement of the contingent earnout liability and other derivative liabilities — a bookkeeping item, not cash generation.

Analysis — what it means for markets and sectors

The second-order read here runs through the dialysis market rather than the trauma market Humacyte already serves. If the FDA grants the dialysis-access indication, Humacyte would compete for hemodialysis access procedures against autogenous AV fistulas, the current standard of care. The company said its V012 Phase 3 trial observed women implanted with the ATEV achieving functional access more than three months sooner and spending significantly more time free of dialysis catheters over the first year than women receiving an AV fistula.

Investors should weigh a clear counter-argument. The $1.0 million quarter and the $64.9 million cash balance imply that Humacyte remains dependent on external financing or partnership revenue to fund a dialysis launch, and the company disclosed no committed financing. The sBLA is a filing, not an approval, and the report does not state a PDUFA date.

Positioning is difficult to infer from the release alone. What the numbers do show is that operating cash burn is falling — $15.0 million for the quarter versus $23.9 million a year earlier — which extends the runway at the current cash level, though the company did not quantify that runway.

The litigation reserve is a reminder that Humacyte carries a shareholder suit overhang into the launch period, and the company did not disclose the settlement terms.

Outlook — what to watch next

Three dates frame the next two quarters. First, the planned November 2026 sBLA submission for the ATEV in dialysis access; the company said the filing is on track. Second, fourth-quarter 2026 Symvess sales, which management expects to at least double the third quarter's $1.0 million — a target that would require roughly $2.0 million in the quarter after October's $0.8 million start.

Third, the Phase 2a study of the CTEV in coronary artery bypass grafting, initiated in November 2026 with the first clinical site activated. Humacyte said it completed the first large-scale manufacturing lot of CTEV at commercial scale.

The report gives no price levels, moving averages or analyst estimates to watch. The observable variables are hospital count — 49 as of 30 September, with at least 20 more expected in the second half — and the monthly sales trajectory that October's $0.8 million has begun.

Frequently Asked Questions

What does Humacyte's Q3 2026 revenue mean for retail investors?

Humacyte's third-quarter Symvess sales of $1.0 million are small in absolute terms but grew 151% sequentially and 43% year over year. The company is still unprofitable, with a $15.5 million quarterly net loss, so the investment case rests on whether the dialysis-access sBLA is approved and whether hospital adoption continues to expand beyond the 49 hospitals ordering as of 30 September 2026.

What happens next for Humacyte's ATEV in dialysis access?

The company said it plans to submit a supplemental Biologics License Application to the FDA in November 2026, supported by three Phase 3 studies. Two have been disclosed: V007, published in The Lancet Digital Health, and V012, presented at ASN Kidney Week 2026. The report does not state when the FDA must respond, and the ATEV remains investigational for dialysis access until any approval.

Why did Humacyte's cost of goods sold rise so much?

Cost of goods sold was $1.4 million in the quarter versus $0.3 million a year earlier. Only $0.6 million reflected units actually sold; $0.8 million was overhead from unused production capacity and royalties. That structure means Humacyte's manufacturing base is built for volumes far above current Symvess demand, so reported gross margin stays negative until sales scale.

Bottom Line

Humacyte's Symvess sales doubled sequentially to $1.0 million, but a November dialysis sBLA filing and continued hospital adoption now carry the investment case.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.